Abstract:Background: Accurate interpretation of BRCA1/2 variants is critical for risk assessment, enhanced cancer surveillance, prevention strategies, and precise clinical treatment of breast cancer. However, current worldwide standards depend primarily on sequencing information from Caucasian populations.Methods: Panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 breast cancer patients (BCs) and 6,434 healthy controls (HCs).Findings: 1,245 pathogenic variants of BRCA1/2, 262 of which were novel (21.04%), and 2,517 variants of uncertain significance (VUS) were identified. Unlike in the Caucasian population, BRCA2 variants were more frequent than BRCA1 variants (56.34% versus 43.66%). The 48 most common variants accounted for 39.86% of all pathogenic variants, and were not reported as common variants in Caucasians. Furthermore, we unambiguously reclassified VUS in 508 subjects, lowering the VUS ratio from 9.05% to 7.21%. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC, invasive carcinomas, high histological grades, and family history of BC and other cancers.Interpretation: Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.Funding Statement: National Natural Science Foundation of China 81772802, Shanghai science and technology innovation action plan of China 17JC1404400 and 16DZ19102, Special Funds for Technological Innovation of Shanghai Jiao Tong University YG2016MS22, Chinese Academy of Science XDA12020223 (W.H.X), Natural Science Foundation of Zhejiang Province LZ16H160002 (C.Y.D), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (C.Y.D).Declaration of Interests: Authors declare no potential conflicts of interest.Ethics Approval Statement: The study was approved by the Ethics Committee of all the hospitals involved and was performed according to the Declaration of Helsinki Principles. Written consent to notify blood samples for future research was obtained for each patient under the Institutional Review Board (IRB)-approved protocol.

BRCA1 and BRCA2 Deleterious Mutation in 219 Han Chinese Hereditary Breast Cancer Patients

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

[BRCA1/2 Gene Mutation in Chinese Familial Breast Cancer Patients: a Multi-Center Report of 115 Cases].

The Prevalence of BRCA1 and BRCA2 Germline Mutations in High-Risk Breast Cancer Patients of Chinese Han Nationality: Two Recurrent Mutations Were Identified

BRCA1 and BRCA2 Gene Mutations of Familial Breast Cancer from Shanghai in China

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

[BRCA1 Germ Line Mutations in Chinese Early-Onset Breast Cancer Patients].

Germline RECQL Gene Mutations in Chinese Patients with Breast Cancer

BRCA1 and BRCA2 Gene Mutations of Familial Breast Cancer and Early-Onset Breast Cancer from Hunan Province in China

Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing

BRCA1 Germline Mutations in Chinese Patients with Hereditary Breast and Ovarian Cancer.

<i>BRCA1</i> c.5470_5477del, a founder mutation in Chinese Han breast cancer patients

Breast cancer risk in BRCA1 and BRCA2 mutation carriers in Chinese Han population

[Mutational Analysis of BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients in Shanghai].

Analysis of BRCA1 Mutations in Chinese Patients with Early Onset Breast Cancer and Affected Relatives

The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Brca1 Germline Mutations and Tumor Characteristics in Chinese Women with Familial or Early-Onset Breast Cancer

The Prevalence of BRCA1 and BRCA2 Mutations in Eastern Chinese Women with Breast Cancer